Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-05-29
2007-05-29
Landsman, Robert S. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S252300, C435S320100, C435S325000, C435S471000
Reexamination Certificate
active
10303502
ABSTRACT:
The present invention relates to novel receptors in the TNF family. A novel receptor has been identified, referred to herein as TRAIN. The invention relates to DNA sequences encoding TRAIN receptors. The invention also contemplates recombinant DNAs comprising a sequence encoding TRAIN receptors or fragments thereof, as well as hosts with stably integrated TRAIN-R sequences introduced into their genome, or possessing episomal elements.
REFERENCES:
patent: 5225538 (1993-07-01), Capon et al.
patent: 2002/0068696 (2002-06-01), Wood et al.
patent: 2003/0219860 (2003-11-01), Tschopp et al.
patent: 2004/0142423 (2004-07-01), Tada et al.
patent: 2006/0058223 (2006-03-01), Mi et al.
patent: 0990703 (2000-04-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 98/01554 (1998-01-01), None
patent: WO 98/38304 (1998-03-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/13078 (1999-03-01), None
patent: WO 99/20644 (1999-04-01), None
patent: WO 99/33967 (1999-07-01), None
patent: WO 99/33980 (1999-07-01), None
patent: WO 99/37818 (1999-07-01), None
patent: WO 00/01817 (2000-01-01), None
patent: WO 2006/017673 (2000-01-01), None
patent: WO 00/49149 (2000-08-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 01/38526 (2001-05-01), None
patent: WO 01/58954 (2001-08-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/93983 (2001-12-01), None
patent: WO 02/00690 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
patent: WO 02/08288 (2002-01-01), None
patent: WO 03/013578 (2003-02-01), None
patent: WO 2005/058028 (2005-06-01), None
Skolnick et al. Trends in Biotech. 18:34-39, 2000.
Bork P. Genome Research 10:398-400, 2000.
Doerks et al. Trends in Genetics 14:248-250, 1998.
Smith et al. Nature Biotechnology 15:1222-1223, 1997.
Brenner SE. Trends in Genetics 15:132-133, 1999.
Bork, et al. Trends in Genetics 12:425-427, 1996.
Aggarwal et al., “Tumor Necrosis Factors: Developments During the Last Decade,”Eur. Cytokine Netw, 7:93-124 (1996).
Bazzoni et al., “The Tumor Necrosis Factor Ligand and Receptor Families,”N Engl. J. Med., 334:1717-1725 (1996).
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Res. 10:39-400 (2000).
Eason et al., “Evaluation of Recombinant Human Soluble Dimeric Tumor Necrosis Factor Receptor for Prevention of OKT3-associated Acute Clinical Syndrome,”Transplantation, 61:224-228 (1996).
Eggermont et al., “Isolated Limb Perfusion with High-Dose Tumor Necrosis Factor-Alpha in Combination With Interferon-Gamma and Melphalan for Nonresectable Extremity Soft Tissue Sarcomas: A Multicenter Trial,”J. Clin. Oncol., 14:2653-2665 (1996).
Feldmann et al., “Role of Cytokines in Rheumatoid Arthritis,”Annu. Rev. Immunol., 14:397-440 (1996).
Green et al., “Fas-Ligand: Privilege And Peril.,”Proc. Natl. Acad. Sci. USA, 94:5986-5990 (1997).
Banner, D.W., et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation,”Cell 73:431-445, Cell Press (1993).
Bodmer, J.-L., et al., “The molecular architecture of the TNF superfamily,”Trends Biomed. Sci. 27:19-26, Elsevier Science Ltd. (Jan. 2002).
Eby, M.T., et al., “TAJ, a Novel Member of the Tumor Necrosis Factor Receptor Family, Activates the c-Jun N-terminal Kinase Pathway and Mediates Caspase-independent Cell Death,”J. Biol. Chem. 275:15336-15342, The American Society for Biochemistry and Molecular Biology, Inc. (May 2000).
Hisaoka, T., et al., “Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing mouse brain,”Develop. Brain Res. 143:105-109, Elsevier Science B.V. (Jun. 2003).
Kojima, T., et al., “TROY, a Newly Identified Member of the Tumor Necrosis Factor Receptor Superfamily, Exhibits a Homology with Edar and Is Expressed in Embryonic Skin and Hair Follicles,”J. Biol. Chem. 275:20742-20747, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 2000).
Mandemakers, W.J. and Barres, B.A., “Axon Regeneration: It's Getting Crowded at the Gates of TROY,”Curr. Biol. 15:R302-R305, Cell Press (Apr. 2005).
Robertson, N.G., et al., “Isolation of Novel and Known Genes from a Human Fetal Cochlear cDNA Library Using Subtractive Hybridization and Differential Screening,”Genomics 23:42-50, Academic Press, Inc. (1994).
Shao, Z., et al., “TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration,”Neuron 45:353-359, Elsevier Inc. (Feb. 2005).
Wang, Y., et al., “An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression,”J. Cell Sci. 117:1525-1532, The Company of Biologists (Mar. 2004).
Wilson, C.A. and Browning, J.L., “Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis,”Cell Death Diff. 9:1321-1333, Nature Publishing Group (Dec. 2002).
NCBI Entrez, Accession No. AAF71828, Eby, M.T., et al. (May 25, 2000).
NCBI Entrez, Accession No. NP—061117, Clark, H.F., et al. (Jul. 5, 2000).
NCBI Entrez, Accession No. BAB03269, Kojima, T., et al. (Jul. 22, 2000).
NCBI Entrez, Accession No. AAK28396, Chaudhary, D. and Long A.J. (Apr. 2, 2001).
NCBI Entrez, Accession No. Q9NS68, Eby, M.T., et al. (May 30, 2002).
NCBI Entrez, Accession No. NM—148957, Clark, H.F., et al. (Sep. 20, 2002).
NCBI Entrez, Accession No. AY358888, Clark, H.F., et al. (Oct. 1, 2003).
NCBI Entrez, Accession No. CAH70838, Pearce, A. (Nov. 9, 2004).
NCBI Entrez, Accession No. BC047321, Strausberg, R.L., et al. (Mar. 3, 2003).
Mikayama et al., “Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor,”Proc. Natl. Acad. Sci. USA, 90:10056-10060 (1993).
Skolnick et al., “From Genes to Proteins Structure and Function: Novel Applications of Computational Approaches in the Genomic Area,”Trends Biotechnol., 18:34-39 (2000).
Smith, “Virus Strategies for Evasion of the Host Response to Infection,”Trends Microbiol., 2:81-88 (1994).
Smith et al., “CD30 Antigen, a Marker for Hodgkin's Lymphoma, is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF,”Cell, 73:1349-1360 (1993).
Smith et al., “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,”Cell, 76:959-962 (1994).
van Dullemen et al., “Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2),”Gastroenterology, 109:129-135 (1995).
Hession Catherine
Tschopp Jurg
Apoxis S.A.
Biogen IDEC MA Inc.
Landsman Robert S.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Nucleic acids encoding TRAIN-R: a cysteine rich member of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding TRAIN-R: a cysteine rich member of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding TRAIN-R: a cysteine rich member of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785752